DEF: KALA BIO Seeks Shareholder Approval for Key Capital Actions

KALA BIO, Inc. announces its 2025 Annual Meeting of Stockholders to vote on director elections, executive compensation, auditor ratification, preferred stock conversion, increased authorized shares, and a reverse stock split.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on January 30, 2026, at 11:00 a.m., Eastern Time.
• Stockholders will vote on the election of three Class II directors: David Lazar, Mark Iwicki, and Todd Bazemore, each to serve until the 2028 annual meeting.
• An advisory, non-binding vote on executive compensation will be held.
• Stockholders will consider the ratification of HTL International, LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• Approval is sought for the issuance of common stock upon conversion of Series AA Convertible Preferred Stock and Series AAA Convertible Preferred Stock, in accordance with Nasdaq Listing Rules 5635(b) and 5635(d).
• An amendment to the Restated Certificate of Incorporation to increase the number of authorized shares of common stock to 1,500,000,000 requires stockholder approval.
• Approval is also sought for an amendment to effect a reverse stock split of common stock at a ratio of not less than 1-for-2 and not greater than 1-for-100, with the exact ratio and timing at the board's discretion.
• Approval for an adjournment of the annual meeting, if necessary, to solicit additional proxies or in the absence of a quorum, will be considered.
• David Lazar was appointed Chief Executive Officer, Chief Financial Officer, President, Chief Operating Officer, and Chair of the Board in November 2025.
• A new financing and balance sheet restructuring was initiated in November 2025, including a securities purchase agreement with David Lazar for up to $6.0 million in preferred equity and a loan settlement with Oxford.
• The first closing of the preferred equity raise on November 24, 2025, involved the issuance of 900,000 shares of Series AA Preferred Stock for $1.8 million.
• The second closing, for 2,100,000 shares of Series AAA Preferred Stock for $4.2 million (of which $1.0 million was paid to Oxford), is conditioned on stockholder approvals.
• The Series AA Preferred Stock is initially convertible into 55 shares of common stock per preferred share, and the Series AAA Preferred Stock into 420 shares of common stock per preferred share, subject to adjustment.
• The loan settlement with Oxford involved a $2.0 million cash payment and the issuance of 1,620,000 shares of common stock.
• Deloitte & Touche LLP was dismissed as the independent registered public accounting firm on December 15, 2025, and HTL International, LLC was appointed for the fiscal year ending December 31, 2025.
• Net Income/(Loss) for 2024 was $(38,511) thousand, for 2023 was $(42,199) thousand, and for 2022 was $(44,822) thousand.
• Total Shareholder Return (TSR) for a $100 investment on December 31, 2021, was $6.94 by December 31, 2024.

Sentiment

Score: 3

Explanation: While the company is actively pursuing financing and restructuring to address its balance sheet and Nasdaq listing requirements, the underlying financial performance (consistent net losses, significant decline in TSR) and the necessity of a reverse stock split and highly dilutive preferred stock conversions point to a precarious financial state. The proposals are critical for survival and continued operations, rather than indicating strong growth or positive performance.

Positives

• A new financing and balance sheet restructuring plan has been initiated to secure needed capital and maintain Nasdaq listing compliance.
• The first closing of the preferred equity raise successfully secured $1.8 million.
• Outstanding loan obligations with Oxford have been settled, reducing financial liabilities.
• The board of directors recommends approval of all proposals, indicating a unified strategic direction for addressing current challenges.
• The virtual meeting format is expected to facilitate greater stockholder attendance and participation from any location.

Negatives

• The necessity of a reverse stock split (Proposal 6) typically indicates a low share price, potentially below Nasdaq minimums, reflecting poor market performance.
• The potential conversion of Series AA and Series AAA Preferred Stock into common stock could result in significant dilution for existing common stockholders (49.5 million and 882 million common shares, respectively).
• The company reported consistent net losses for 2022 ($(44,822) thousand), 2023 ($(42,199) thousand), and 2024 ($(38,511) thousand), indicating ongoing unprofitability.
• Total Shareholder Return (TSR) for a $100 investment on December 31, 2021, declined significantly to $6.94 by December 31, 2024, representing substantial value destruction.
• High expected volatility for stock options (103.47% 114.24% in 2024) suggests a high-risk investment profile.

Risks

• Failure to obtain stockholder approval for the preferred stock conversion (Proposal 4) and the authorized share increase (Proposal 5) could adversely affect the company's financing and capital structure objectives, including the second closing of the Series AAA preferred stock and the Oxford loan settlement.
• The conversion of Series AA and Series AAA Preferred Stock into common stock carries a significant risk of dilution for existing common stockholders.
• Concentrated ownership resulting from preferred stock conversions could enable significant influence over matters submitted to a stockholder vote, including director elections and corporate transactions.
• There is a risk of failing to maintain Nasdaq continued listing standards if capital structure issues are not adequately addressed.
• The company faces general business strategy, acquisitions and divestitures, capital allocation, and organizational structure risks.
• Cybersecurity and other information technology risks are overseen by the audit committee.

Future Outlook

The company anticipates the second closing of the Series AAA Preferred Stock financing to occur promptly following stockholder approval and prior to March 31, 2026, contingent on specific conditions. If Proposal 5 is approved, the company intends to promptly file the charter amendment to increase authorized common shares. The board reserves the right to abandon the reverse stock split if it is deemed not in the best interests of the company and stockholders. The compensation committee plans to continue engaging independent compensation consultants for executive and director compensation programs and competitive benchmarking.

Management Comments

• "We believe that hosting a virtual meeting will enable greater stockholder attendance and participation from any location around the world."
• "Thank you for your ongoing support and continued interest in Kala."
• "Our board believes that combining the Chair and Chief Executive Officer positions fosters clear accountability, effective decision-making and alignment of corporate strategy and is the appropriate leadership structure for us at this time."
• "Our board believes that Mr. Lazars combined role of Chair and Chief Executive Officer promotes effective execution of strategic goals and facilitates information flow between management and our board."
• "Our executive compensation programs are designed to attract, motivate, and retain our executive officers, who are critical to our success."
• "Our executive compensation embodies a pay-for-performance philosophy that supports our business strategy, aligns the interests of our executives with our stockholders and promotes company performance."
• "At the same time, we believe our program does not encourage excessive risk-taking by management."

Industry Context

KALA BIO operates within the biopharmaceutical industry, a sector characterized by high R&D costs, regulatory hurdles, and significant capital requirements. The company's current actions, including capital raises and a proposed reverse stock split, reflect common challenges faced by smaller biopharmaceutical firms in maintaining liquidity, funding development, and adhering to exchange listing standards. The emphasis on corporate governance and executive compensation aligns with broader industry trends towards increased transparency and accountability.

Comparison to Industry Standards

• The filing does not provide specific comparisons to comparable companies, projects, or results within the biopharmaceutical industry.
• The compensation committee states it considers publicly available compensation data for national and regional companies in the biotechnology/pharmaceutical industry to guide its executive compensation decisions.

Management Changes

Corporate Governance

Related Party Transactions

• In the 2024 Private Placement, entities affiliated with Baker Bros. Advisors LP (including Baker Brothers Life Sciences, L.P. and 667, L.P.) purchased 4,507,359 shares of common stock for an aggregate purchase price of $2,000,000.00.
• SR One Capital Fund II Aggregator, LP purchased 155,279 shares of common stock for $999,996.76 in the 2024 Private Placement.
• Cormorant Global Healthcare Master Fund, LP purchased 603,027 shares of common stock and 3,286 shares of Series I Preferred Stock for $5,999,677.88 in the 2024 Private Placement.
• David Lazar entered into a Securities Purchase Agreement on November 23, 2025, to purchase preferred stock for up to $6.0 million, with the first closing on November 24, 2025, for $1.8 million in Series AA Preferred Stock.
• David Lazar entered into a Convertible Loan Agreement for $375,000 on November 9, 2025, which was repaid on December 18, 2025.
• A Voting Agreement was entered into with David Lazar and Oxford on November 23, 2025, where Oxford agreed to vote its shares in favor of board-recommended proposals.
• Indemnification agreements have been entered into with all directors and officers.

Stakeholder Impact

• **Shareholders**: Face potential significant dilution from the conversion of Series AA and Series AAA Preferred Stock and the proposed reverse stock split. The negative TSR indicates poor historical returns. They have the opportunity to vote on critical proposals affecting the company's future capital structure and Nasdaq listing.
• **Employees**: Executive compensation programs are designed to attract, motivate, and retain talent. Settlement agreements for severance rights were made with Todd Bazemore and Kim Brazzell. A 401(k) plan with company match is in place.
• **Creditors**: The Oxford loan settlement addresses outstanding obligations, potentially improving the company's credit profile and reducing immediate debt burden.
• **Management**: New leadership under David Lazar is implementing a significant restructuring. Executive compensation is tied to performance, and a clawback policy is in effect for erroneously awarded compensation.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders on January 30, 2026, to vote on all proposed matters.
• Proceed with the second closing of the Series AAA Preferred Stock financing promptly after stockholder approvals and prior to March 31, 2026.
• If Proposal 5 is approved, promptly file the charter amendment to increase authorized common shares.
• Publicly disclose the board's decision regarding any director resignation if a Majority Withhold Vote occurs.
• File a Current Report on Form 8-K with final voting results within four business days following the annual meeting.
• Stockholder proposals for the 2026 annual meeting to be considered for inclusion in the proxy statement must be received by September 1, 2026.

Key Dates

Recommendation

The filing reveals a company in a distressed financial state, evidenced by consistent net losses, a severely negative Total Shareholder Return over three years, and the necessity of a reverse stock split to maintain Nasdaq compliance. The proposed capital raise, while critical for survival, involves highly dilutive preferred stock conversions that will significantly impact existing common shareholders. The agreement for current directors (except the new CEO) to resign if certain proposals pass further signals a significant restructuring under new leadership, which carries inherent uncertainty. Given the substantial dilution, poor historical performance, and the need for drastic capital structure changes, the stock presents a high-risk profile with limited upside for current common shareholders.

Keywords

Proxy Statement, Annual Meeting, Stockholder Vote, Reverse Stock Split, Authorized Shares Increase, Convertible Preferred Stock, Nasdaq Listing Rules, Executive Compensation, Director Election, Auditor Ratification, Capital Raise, Balance Sheet Restructuring, KALA BIO, Biopharmaceutical